In 1992 in El Paso, TX a randomized, double-blind, placebo controlled study of subjects (n=130) with allergic rhinitis in 1992-1993 was conducted. The average IgE level of the placebo treated subjects remained essentially eczema and treatment flat, while the average IgE level for active eczema treated subjects was reduced significantly from baseline to Day 30.7 In 1993 in El treatment Paso, TX, valid subjects (n=66) returned a second set eczema of symptom diaries which they had completed for days 365 to 395 (the same period, one year after treatment and eczema the first set of symptom treatment diaries). eczema The active group treatment had mean symptom scores showing statistically significant decreases eczema from 1992 to 1993. The placebo group had increased symptoms in 1993. (The relevant pollen counts at the study site in 1993 were much higher than in 1992, leading to expectation of higher symptoms.)7

Genentech and Novartis are developing an treatment anti-IgE monoclonal antibody for asthma and allergic rhinitis. In December 1999 they announced positive study results. This is evidence that reducing IgE results in a reduction of symptoms associated with IgE-mediated eczema and treatment allergic disease.13 For people who find they cannot adequately avoid the allergens, the symptoms often can be controlled with medications. Effective medications that can be prescribed by a physician include antihistamines, topical nasal steroids, and cromolyn sodium - any of which can be used alone or in combination. Many effective antihistamines and decongestants also are available without a prescription. eczema Click treatment here for allergy medication online eczema and treatment.

©2003 www.female-prenatal-supplements.com All rights reserved.